- Home
- MBIN vs TARS Comparison
MBIN vs TARS Comparison
Compare MBIN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBIN | TARS |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | 735 | 370 |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBIN | TARS |
|---|---|---|
| Price | $46.64 | $63.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $43.67 | ★ $89.00 |
| AVG Volume (30 Days) | 116.5K | ★ 638.3K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $31.76 | $56.43 |
| Revenue Next Year | $3.73 | $30.19 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $28.75 | $38.51 |
| 52 Week High | $50.26 | $85.25 |
Technical Indicators
Market Signals| Indicator | MBIN | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 49.22 |
| Support Level | $45.12 | $60.38 |
| Resistance Level | $48.50 | $67.24 |
| Average True Range (ATR) | 1.32 | 3.64 |
| MACD | -0.12 | 0.36 |
| Stochastic Oscillator | 74.36 | 67.50 |
Price Performance
Historical ComparisonAbout MBIN Merchants Bancorp
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.